中风与神经疾病杂志2025，Vol.42Issue(12)：1150-1152,3.DOI:10.19845/j.cnki.zfysjjbzz.2025.0208
垂体腺苷酸环化酶激活肽38与偏头痛的研究进展
Research advances in pituitary adenylate cyclase activating polypeptide 38 and migraine
摘要
Abstract
Pituitary adenylate cyclase activating polypeptide(PACAP),as an important neuropeptide,plays a key role in the pathophysiological process of migraine.Although current anti-(calcitonin gene-related peptide,CGRP)targeted therapy has become a major breakthrough in migraine treatment,some patients show suboptimal responses to anti-CGRP therapy.In recent years,PACAP-38 has attracted significant attention as a potential novel therapeutic target.This article systematically reviews the molecular characteristics of PACAP-38,its pathological association with migraine,and the lat-est research advances in related targeted drugs,in order to provide new ideas for the precise treatment of migraine.关键词
神经肽/垂体腺苷酸环化酶激活肽/偏头痛/靶向治疗Key words
Neuropeptide/Pituitary adenylate cyclase activating polypeptide/Migraine/Targeted therapy分类
医药卫生引用本文复制引用
晏鑫雨,万东君..垂体腺苷酸环化酶激活肽38与偏头痛的研究进展[J].中风与神经疾病杂志,2025,42(12):1150-1152,3.基金项目
中央高校基本科研业务费专项资金项目(31920250056) （31920250056）
